Hematologic Malignancies

  • Marc Gautier
  • Harvey Jay Cohen


The hematologic malignancies are a diverse group of disorders that are frequently considered together because they consist of clonal expansions of hematopoietic cells. The cell of origin of many of the hematologic malignancies is known. The stage of differentiation of the transformed cell essentially determines the phenotype of the disorder. Before considering the types of hematologic malignancies, we will review the normal differentiation pathway of hematopoietic cells.


Multiple Myeloma Acute Myelocytic Leukemia Chronic Lymphocytic Leukemia Acute Leukemia Polycythemia Vera 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Preti A, Kantarjian HM. Management of adult acute lym- 20. phocytic leukemia: present issues and key challenges. J Clin Oncol. 1994; 12: 1312–1322.PubMedGoogle Scholar
  2. 2.
    Hoelzer DF. Therapy of the newly diagnosed adult with acute lymphoblastic leukemia. Hematol Oncol Clin North 21. Am. 1993; 7: 139–160.Google Scholar
  3. 3.
    Harousseau J-L. Is intensive treatment beneficial to elderly 22. patients with ANLL? Hematol Oncol. 1993; 11: 4–8.PubMedGoogle Scholar
  4. 4.
    Foon KA, Zighelboim J, Yale C, et al. Intensive chemotherapy is the treatment of choice for elderly patients with 23. acute myelogenous leukemia. Blood. 1981; 58: 467–470.PubMedGoogle Scholar
  5. 5.
    Tallman MS, Rowe JM. Acute promyelocytic leukemia: a paradigm for differentiation therapy with retinoic acid. Blood Rev. 1994; 8: 70–78. 24.Google Scholar
  6. 6.
    Kourdes PA, Bennett JM. Morphology and classification of myelodysplastic syndromes. Hematol Oncol Clin North 25. Am. 1992; 6: 485–500.Google Scholar
  7. 7.
    Mufti GJ. A guide to risk assessment in the primary 26. myelodysplastic syndrome. Hematol Oncol Clin North Am. 1992; 6: 587–606.PubMedGoogle Scholar
  8. 8.
    Noel P, Solberg LA. Myelodysplastic syndromes. Crit Rev 27. Oncol Hematol. 1992; 12: 193–215.Google Scholar
  9. 9.
    Kantarjian HM, Deisseroth A, Kurzrock R, et al. Chronic myelogenous leukemia: a concise update. Blood. 1993; 28. 82: 691–703.Google Scholar
  10. 10.
    Tura S, Baccarani M, Zuffa E, et al. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med. 29. 1994; 330: 820–825.Google Scholar
  11. 11.
    Miller JS, McGlave PB. Therapy for chronic myelogenous leukemia with marrow transplantation. Curr Opin Oncol. 1993; 5: 262–269.PubMedCrossRefGoogle Scholar
  12. 12.
    Prchal JT, Prchal JF. Evolving understanding of the cellular defect in polycythemia vera: applications for its clinical diagnosis and molecular pathophysiology. Blood. 1994; 83: 1–4.PubMedGoogle Scholar
  13. 13.
    Tura S. The management of elderly patients with myeloproliferative disorders. Hematol Oncol. 1993; 11: 39–41.PubMedGoogle Scholar
  14. 14.
    Silver RT. Interferon-a2b: a new treatment for polycythemia vera. Ann Intern Med. 1993; 119: 1091–1092.PubMedGoogle Scholar
  15. 15.
    Benbassat J, Gilon D, Penchas S. The choice between splenectomy and medical treatment in patients with advanced agnogenic myeloid metaplasia. Am J Hematol. 1990; 33: 128–135.PubMedCrossRefGoogle Scholar
  16. 16.
    Oscier DG. Cytogenetic and molecular abnormalities in chronic lymphocytic leukaemia. Blood Rev. 1994; 8: 88–97.PubMedCrossRefGoogle Scholar
  17. 17.
    Rozman C, Montserrat E, Rodriquez-Fernandez JM, et al. Bone marrow histologic pattern, the best single prognostic parameter in chronic lymphocytic leukemia: a multivariate survival analysis of 329 cases. Blood. 1984; 64: 642.PubMedGoogle Scholar
  18. 18.
    Keating MJ, McLaughlin P, Plunkett W, et al. Fludarabine-present status and future developments in chronic lymphocytic leukemia and lymphoma. Ann Oncol. 1994; 5 (suppl 2): 79–83.PubMedCrossRefGoogle Scholar
  19. 19.
    Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized controlled clinical trial. N Engl J Med. 1988; 319: 902.CrossRefGoogle Scholar
  20. 20.
    Smalley RV, Connors J, Tuttle RL, et al. Splenectomy vs alpha interferon: a randomized study in patients with previously untreated hairy cell leukemia. Am J Hematol. 1992; 41: 13–18.PubMedCrossRefGoogle Scholar
  21. 21.
    Saven A, Piro L. Newer purine analogues for the treatment of hairy-cell leukemia. N Engl J Med. 1994; 330: 691–697.PubMedCrossRefGoogle Scholar
  22. 22.
    Crawford J, Eye MK, Cohen HJ. Evaluation of monoclonal gammopathies in the “well” elderly. Am J Med. 1987; 82: 39–45.PubMedCrossRefGoogle Scholar
  23. 23.
    Kyle RA. Plasma cell proliferative disorders. In: Hoffman R, Benz EJ, Shattil SJ, Furie B, et al., eds. Hematology Basic Principles and Practice. New York: Churchill-Livingstone; 1991: 1021–1038.Google Scholar
  24. 24.
    Kyle RA. Current concepts on monoclonal gammopathies. Aust NZ J Med. 1992; 22: 291–302.CrossRefGoogle Scholar
  25. 25.
    Gautier M, Cohen HJ. Multiple myeloma in the elderly. J Am Geriatr Soc. 1994; 42: 653–664.PubMedGoogle Scholar
  26. 26.
    Paquette RL, Berenson J, Lichtenstein A, et al. Oncogenes in multiple myeloma: point mutation of N-ras. Oncogene. 1990; 5: 1659–1663.Google Scholar
  27. 27.
    Bataille R, Chappard D, Klein B. Mechanisms of bone lesions in multiple myeloma. Hematol Oncol Clin North Am. 1992; 6: 285–295.PubMedGoogle Scholar
  28. 28.
    Gregory WM, Richards MA, Malpas JS. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol. 1992; 10: 334–342.PubMedGoogle Scholar
  29. 29.
    Buzaid AC, Durie BGM. Management of refractory myeloma: a review. J Clin Oncol. 1988; 6: 889–905.PubMedGoogle Scholar
  30. 30.
    Sonneveld P, Durie BGM, Lokhorst HM, et al. Modulation of multidrug-resistant multiple myeloma by cyclosporin. Lancet. 1992; 340: 255–259.PubMedCrossRefGoogle Scholar
  31. 31.
    Mandelli F, Avvisati G, Amadori S, et al. Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med. 1990; 322: 1430–1434.PubMedCrossRefGoogle Scholar
  32. 32.
    Klein B, Wijdenes J, Zhang XG, et al. Murine anti-interleukin-6 monoclonal antibody therapy for apatient with plasma cell leukemia. Blood. 1991; 78: 1198 1204.Google Scholar
  33. 33.
    Ludwig H, Fritz E, Kotzmann H, et al. Erythropoietin treat ment of anemia associated with multiple myeloma. N Engl J Med. 1990; 322: 1693–1699.Google Scholar
  34. 34.
    Crawford J, Cox EB, Cohen HJ. Evaluation of hyperviscosity in monoclonal gammopathies. Am J Med. 1985; 79: 13.PubMedCrossRefGoogle Scholar
  35. 35.
    Gertz MA, Kyle RA, Greipp PR. Response rates and sur vival in primary systemic amyloidosis. Blood. 1991; 77: 257–262.PubMedGoogle Scholar
  36. 36.
    Weisenburger DD. Epidemiology of non-Hodgkin’s lymphoma: recent findings regarding an emerging epidemic. Ann Oncol. 1994; 5 (suppl 1): 19–24.PubMedCrossRefGoogle Scholar
  37. 37.
    Gaidano G, Dalla-Favera R. Biologic and molecular char acterization of non-Hodgkin’s lymphoma. Curr Opin Oncol. 1993; 5: 776–784.PubMedCrossRefGoogle Scholar
  38. 38.
    Young RC, Longo DL, Glatstein E, et al. The treatment of indolent lymphomas: watchful waiting. V. Aggressive com bined modality treatment. Semin Hematol. 1988; 25: 11.PubMedGoogle Scholar
  39. 39.
    Shipp MA. Prognostic factors in aggressive non-Hodgkin’s lymphoma: who has “high-risk” disease? Blood. 1994; 83: 1165–1173.PubMedGoogle Scholar
  40. 40.
    Dixon DO, Neilan B, Jones SE, et al. Effect of age ontherapeutic outcome in advanced diffuse histiocytic lymphoma: The Southwest Oncology Group experience. J Clin Oncol. 1986; 4: 295–305.PubMedGoogle Scholar
  41. 41.
    Vose JM, Armitage JO, Weisenburger DD, et al. The im portance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 1988; 6: 1838–1844.PubMedGoogle Scholar
  42. 42.
    Mauch PM, Kalish LA, Kadin M, et al. Patterns of presentation of Hodgkin disease: implications for etiology and pathogenesis. Cancer. 1993; 71: 2062–2071.PubMedCrossRefGoogle Scholar
  43. 43.
    Kaufman D, Lungo DL. Hodgkin’s disease. Clin Rev Oncol/Hematol. 1992; 13: 135–187.CrossRefGoogle Scholar
  44. 44.
    Mauch PM. Controversies in the management of early stage Hodgkin’s disease. Blood. 1994; 83: 318–329.PubMedGoogle Scholar
  45. 45.
    DeVita VT, Hubbard SM. Drug therapy: Hodgkin’s dis ease. N Engl J Med. 1993; 328: 560–565.PubMedCrossRefGoogle Scholar
  46. 46.
    Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992; 327: 1478–1484.PubMedCrossRefGoogle Scholar
  47. 47.
    Prosnitz LR, Roberts KB. Combined chemotherapy and radiotherapy for Hodgkin’s disease. Oncology. 1992;6: 113–137.Google Scholar
  48. 48.
    Mir R, Anderson J, Strauchen J, et al. Hodgkin disease in patients 60 years of age or older. Cancer. 1993; 71: 1857–1866.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1997

Authors and Affiliations

  • Marc Gautier
  • Harvey Jay Cohen

There are no affiliations available

Personalised recommendations